Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Proposals include establishing "indirect recognition" of EU CE-marked devices to the UK market and "international reliance" ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

Advanced Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot & Ankle Surgery Market ...

The Good Food Collective, a new coalition of 25-plus food brands, organizations, and nutrition experts, has teamed up to ...

The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine ...

Lawmakers in both chambers have introduced legislation to require the Food and Drug Administration to study the impacts of ...

A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

Outside of hyping healthy foods, some of MAHA’s other priorities are more suspect. The 73-page MAHA report the White House ...

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.